Antineoplastics
1
Reactions 1491, p9 - 8 Mar 2014 (85.7%) and the [hepatic arterial infusion] catheter and subcutaneous implantable port system had to be removed." S Antineoplastics Tajima H, et al. Hepatic arterial infusion chemotherapy with gemcitabine and Various toxicities: 7 case reports 5-fluorouracil or oral S-1 improves the prognosis of patients with postoperative liver metastases from pancreatic cancer. Molecular and Clinical Oncology 1: In a study, 7 patients with liver metastases from pancreatic 869-874, No. 5, Sep 2013. Available from: URL: http://doi.org/10.3892/ cancer developed various toxicities while receiving hepatic mco.2013.152 - Japan 803100176 arterial infusion chemotherapy with gemcitabine and either fluorouracil or gimeracil/oteracil/tegafur [some routes not stated; duration of therapy before reaction onsets and outcomes not stated]; all patients eventually died from their primary disease. A 61-year-old woman received intrahepatic arterial infusion chemotherapy, with each biweekly cycle comprising gemcitabine 400mg/standard liver volume dissolved in saline 50mL administered over 30 minutes, then fluorouracil 250mg/ standard liver volume dissolved in saline 50mL infused continuously over 24 hours on days 1–5. During therapy she developed grade 2 anaemia, grade 3 leucopenia and grade 2 thrombocytopenia, and catheter complications leading to removal of the subcutaneous implantable port system. A 62-year-old man received intrahepatic arterial infusion chemotherapy, with each biweekly cycle comprising gemcitabine 800mg/standard liver volume dissolved in saline 50mL administered over 30 minutes, then fluorouracil 250mg/ standard liver volume dissolved in saline 50mL infused continuously over 24 hours on days 1–5. During therapy he developed grade 2 anaemia, grade 1 thrombocytopenia, and catheter complications leading to removal of the subcutaneous implantable port system. A 69-year-old man received intrahepatic arterial infusion chemotherapy, with each biweekly cycle comprising gemcitabine 800mg/standard liver volume dissolved in saline 50mL administered over 30 minutes, then fluorouracil 250mg/ standard liver volume dissolved in saline 50mL infused continuously over 24 hours on days 1–5. During therapy he developed grade 1 anaemia. A 71-year-old man received intrahepatic arterial infusion chemotherapy, with each biweekly cycle comprising gemcitabine 800mg/standard liver volume dissolved in saline 50mL administered over 30 minutes, then fluorouracil 250mg/ standard liver volume dissolved in saline 50mL infused continuously over 24 hours on days 1–5. During therapy he developed grade 1 anaemia, grade 2 thrombocytopenia, and catheter complications leading to removal of the subcutaneous implantable port system. A 60-year-old woman received intrahepatic arterial infusion chemotherapy, with each biweekly cycle comprising gemcitabine 800mg/standard liver volume dissolved in saline 50mL administered over 30 minutes, then fluorouracil 250mg/ standard liver volume dissolved in saline 50mL infused continuously over 24 hours on days 1–5. During therapy she developed grade 2 anaemia, and catheter complications leading to removal of the subcutaneous implantable port system. A 66-year-old man received intrahepatic arterial infusion chemotherapy, with each biweekly cycle comprising intrahepatic arterial infusion chemotherapy, with each biweekly cycle comprising gimeracil/oteracil/tegafur 60 mg/m 2 /day for 7 consecutive days and gemcitabine 800mg/ standard liver volume on day 8. During therapy, he developed grade 2 anaemia, grade 2 leucopenia and grade 1 thrombocytopenia. Catheter complications occurred, leading to removal of the subcutaneous implantable port system. A 65-year-old man received intrahepatic arterial infusion chemotherapy, with each biweekly cycle comprising intrahepatic arterial infusion chemotherapy, with each biweekly cycle comprising gimeracil/oteracil/tegafur 60 mg/m 2 /day for 7 consecutive days and gemcitabine 800mg/ standard liver volume on day 8. During therapy, he developed grade 1 anaemia and catheter complications, which lead to removal of the subcutaneous implantable port system. Author comment: "[T]here were no life-threatening toxicities. However, catheter-related complications (arterial thrombosis or catheter dislocation) occurred in 6 cases 1 Reactions 8 Mar 2014 No. 1491 0114-9954/14/1491-0001/$14.95 Adis © 2014 Springer International Publishing AG. All rights reserved
Transcript of Antineoplastics
Reactions 1491, p9 - 8 Mar 2014
(85.7%) and the [hepatic arterial infusion] catheter andsubcutaneous implantable port system had to be removed." SAntineoplasticsTajima H, et al. Hepatic arterial infusion chemotherapy with gemcitabine and
Various toxicities: 7 case reports 5-fluorouracil or oral S-1 improves the prognosis of patients with postoperativeliver metastases from pancreatic cancer. Molecular and Clinical Oncology 1:In a study, 7 patients with liver metastases from pancreatic869-874, No. 5, Sep 2013. Available from: URL: http://doi.org/10.3892/cancer developed various toxicities while receiving hepaticmco.2013.152 - Japan 803100176arterial infusion chemotherapy with gemcitabine and either
fluorouracil or gimeracil/oteracil/tegafur [some routes notstated; duration of therapy before reaction onsets andoutcomes not stated]; all patients eventually died from theirprimary disease.
A 61-year-old woman received intrahepatic arterial infusionchemotherapy, with each biweekly cycle comprisinggemcitabine 400mg/standard liver volume dissolved in saline50mL administered over 30 minutes, then fluorouracil 250mg/standard liver volume dissolved in saline 50mL infusedcontinuously over 24 hours on days 1–5. During therapy shedeveloped grade 2 anaemia, grade 3 leucopenia and grade 2thrombocytopenia, and catheter complications leading toremoval of the subcutaneous implantable port system.
A 62-year-old man received intrahepatic arterial infusionchemotherapy, with each biweekly cycle comprisinggemcitabine 800mg/standard liver volume dissolved in saline50mL administered over 30 minutes, then fluorouracil 250mg/standard liver volume dissolved in saline 50mL infusedcontinuously over 24 hours on days 1–5. During therapy hedeveloped grade 2 anaemia, grade 1 thrombocytopenia, andcatheter complications leading to removal of the subcutaneousimplantable port system.
A 69-year-old man received intrahepatic arterial infusionchemotherapy, with each biweekly cycle comprisinggemcitabine 800mg/standard liver volume dissolved in saline50mL administered over 30 minutes, then fluorouracil 250mg/standard liver volume dissolved in saline 50mL infusedcontinuously over 24 hours on days 1–5. During therapy hedeveloped grade 1 anaemia.
A 71-year-old man received intrahepatic arterial infusionchemotherapy, with each biweekly cycle comprisinggemcitabine 800mg/standard liver volume dissolved in saline50mL administered over 30 minutes, then fluorouracil 250mg/standard liver volume dissolved in saline 50mL infusedcontinuously over 24 hours on days 1–5. During therapy hedeveloped grade 1 anaemia, grade 2 thrombocytopenia, andcatheter complications leading to removal of the subcutaneousimplantable port system.
A 60-year-old woman received intrahepatic arterial infusionchemotherapy, with each biweekly cycle comprisinggemcitabine 800mg/standard liver volume dissolved in saline50mL administered over 30 minutes, then fluorouracil 250mg/standard liver volume dissolved in saline 50mL infusedcontinuously over 24 hours on days 1–5. During therapy shedeveloped grade 2 anaemia, and catheter complicationsleading to removal of the subcutaneous implantable portsystem.
A 66-year-old man received intrahepatic arterial infusionchemotherapy, with each biweekly cycle comprisingintrahepatic arterial infusion chemotherapy, with eachbiweekly cycle comprising gimeracil/oteracil/tegafur60 mg/m2/day for 7 consecutive days and gemcitabine 800mg/standard liver volume on day 8. During therapy, he developedgrade 2 anaemia, grade 2 leucopenia and grade 1thrombocytopenia. Catheter complications occurred, leadingto removal of the subcutaneous implantable port system.
A 65-year-old man received intrahepatic arterial infusionchemotherapy, with each biweekly cycle comprisingintrahepatic arterial infusion chemotherapy, with eachbiweekly cycle comprising gimeracil/oteracil/tegafur60 mg/m2/day for 7 consecutive days and gemcitabine 800mg/standard liver volume on day 8. During therapy, he developedgrade 1 anaemia and catheter complications, which lead toremoval of the subcutaneous implantable port system.
Author comment: "[T]here were no life-threateningtoxicities. However, catheter-related complications (arterialthrombosis or catheter dislocation) occurred in 6 cases
1
Reactions 8 Mar 2014 No. 14910114-9954/14/1491-0001/$14.95 Adis © 2014 Springer International Publishing AG. All rights reserved
